Search Results

Ecosystem: sharper programming, deeper expertise, and renewed momentum across everything we publish and build Community presence  — from conferences to collaborative initiatives built in public. 👉 Email us to chat

Teams stay busy. How Rational Decisions Accumulate Into Drift 👉 Every biotech startup is built on decisions that make patterns: Incremental scope expansion that feels strategic Delayed commitments are justified as prudent Busy simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building

Terry Kenakin, monthly AMAs, and a growing on-demand library built around pharmacology's most important

Business development conversations feel inconsistent, even when the company and the science have not not easier 3️⃣ Partner discussions sound positive, but rarely convert into concrete next steps 4️⃣ Business Investors, partners, and business development teams are not evaluating scientific merit in isolation. This puts the burden of synthesis on the listener , who may not share the same context or priorities. This clarity removes a hidden burden from founders. 👉 They no longer carry the responsibility of making

Budgets are locked. Teams are committed. Assumptions feel too costly to challenge. Business pushes speed. Operations push stability. Execution feels busy but not effective. Teams mistake motion for progress . And it is built far earlier than most teams realize, at the moment when strategic decision-making still earlier through strategic decision-making , when direction is still flexible, and alignment is easy to build

. 👉 The company becomes busy instead of deliberate. The organization stays busy, but learning slows down. 👉 This pattern usually shows up in a very specific Strategy creates a shared filter that connects science execution and business reality. ✅ At its core, It has to be built deliberately and revisited continuously. or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

built . being built This is the most frequent issue investors encounter. In biotech fundraising, coherence builds trust. It fails when intellectual property does not clearly support the business being built.   When science, intellectual property, and business intent reinforce each other, trust builds early and

early-stage biotechs show the same pattern: strong scientific progress paired with an operating cadence built narrative checkpoints, and predictable timeline discipline, the organization typically shifts from “busy Decisions are made once and communicated clearly. 2️⃣ Cadence of Communication: The Rhythm That Builds Teams optimize for activity, not momentum Scientific surprises hit harder because the system has no buffer or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built The strongest discovery programs aren’t built on instrumentation alone—they’re built on interpretation

. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. Clear structure gives your science the visibility and consistency that traction is built on. Meetings end with explanations, not decisions BD calls “went great,” but nothing moves Timelines are built The danger is subtle: 👉Scientific isolation feels busy, intelligent, respectable. , or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start building

Built for pharmacologists strengthening fundamentals, program teams navigating bottlenecks, and leaders

asking better questions in science, not as a skill you’re born with, but one you can intentionally build Building a Scientific Career Through Asking Better Questions in Science Late in the conversation, JB The scientist who asks the best questions builds the strongest network—and the most resilient expertise

They exchanged instincts as much as data, and built a shared rhythm of problem-solving.

Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start It's the test of how well you built it. Building FDA-Ready Thinking into Your Strategy Regulatory success is not a function. If you can’t see them too, you’re not building strategy, you’re building surprises. Because by the time they do, your timelines will stretch, your budgets will strain, and your confidence

observed at higher concentrations, consistent with competitive displacement  These visual layers act as built-in

What followed — a trip to London, confocal imaging marathons, and a partnership built on trust and curiosity Together, they built the first generation of GLP-1R fluorescent ligands — probes precise enough to visualize To build tools that performed consistently, JB and collaborators shifted toward a more rigorous parallelized chemists, theorists, biochemists, toxicologists, and cell biologists — all working toward the same goal: building

But HCS only works when assays are built with rigor and powered by the right fluorescent ligands. It’s a system-aware resource built for researchers who need clarity fast—reinforcing system-level GPCR

. ✅ Start with relevance, not results. 2️⃣ Using buzzwords instead of clarity Words like “platform”, It’s about strategic clarity. ✅ When your pitch follows this logic, it respects the listener’s time, builds It communicates that you know who you’re building for, why now is the right time, and how your solution , or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start building

They fail because a molecule behaved exactly as the underlying system allowed—amplified, buffered, redirected utility emerged from the interplay between β₁-mediated inotropy and α-mediated vascular effects that buffered

The future of discovery will belong to scientists who know how to build the right partnerships and stay Instead of forcing antibodies to do what they weren’t built for, JB’s group engineered fluorescent ligands when the cryo-EM data arrived — a structure solved through the same collaborative network that had built It’s about trust — the kind of trust built when collaborators confirm your data, replicate your results Here’s where the biggest opportunities will emerge: Building receptor-specific delivery systems for gene

Key limitations of radioligand assays include:  • No spatial information  — signals are measured in bulk

The literature was buzzing. Labs were competing.

Meanwhile, researchers in the building across the way turned off the lights at 6 PM.

Schild analysis turns receptor pharmacology into detective work, spotlighting mechanistic fingerprints buried Built for pharmacologists refining tools, discovery teams solving bottlenecks, and leaders seeking credible

Listen to the episode ➤ Quick Links Assess GPCR Biased Signaling of Agonist How GPCR Collaboration Built

Your scientific thinking built the foundation, but leadership is what scales it. waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay critical business But in business, decisions must be made under uncertainty . Clarity doesn’t precede action; it follows it.   2️⃣ “Eliminate error at all costs” Labs are built around or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

That’s not a story about nostalgia — it’s a snapshot of how GPCR research was built, on technique at of GPCR research today — from high-throughput ligand screens to real-time signaling readouts — are built The Evolution of GPCR Research Every generation of GPCR scientists inherits the tools of the last and builds What started as hand-built assays on ice has become integrated platforms for drug discovery, systems

For innovators building tools, platforms, or therapeutics, these origin moments are where tomorrow’s She built on chance moments with deliberate moves—grants pursued, labs chosen, collaborations built. Built to Inspire The story of Michelle Halls isn’t just about a career; it’s about a pattern.

. • Training Builds Innovation : Her lab model at Monash is shaping the next generation of GPCR scientists . 👉 Dive into spatial pharmacology ➤ A Note From Yamina: Building the Next Chapter of Dr.

Building on Known Pharmacology Medicinal chemists learned early that modifying endogenous molecules — Why Terry’s Corner Terry’s Corner is a continuously growing knowledge platform built for scientists